Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 2/2015

01-06-2015 | Risk, Prevention, and Screening (TA Patel, Section Editor)

The Genetic Information Nondiscrimination Act of 2008 (GINA) and the Patient Protection and Affordable Care Act of 2010 (PPACA): What They Mean for Breast Cancer Patients and Their Families

Author: Mary Beth Wilson Steck

Published in: Current Breast Cancer Reports | Issue 2/2015

Login to get access

Abstract

From 2007 to 2011, deaths in females due to breast cancer declined in the USA. This decline has been attributed to improved access to breast cancer screening and subsequent effective treatments for female with invasive breast cancer. In this same time period, two federal health-care policies were enacted, the Genetic Information Nondiscrimination Act of 2008 (GINA), to decrease fear of discrimination based on genetic information (genetics tests results and/or family history) in health insurance and employment arenas, and the Patient Protection and Affordable Care Act of 2010 (PPACA), health-care reform to improve access for breast cancer screening. Health-care providers need to be knowledgeable about GINA and PPACA so they can apply these legislative provisions and be aware of their limitations in their clinical practice of breast cancer patients, in order to effectively advocate for these patients and their families.
Literature
1.
Siebert DC. Genetics and disease prevention: complementary or contradictory? J Nurs Pract. 2010;6(7):507–16.CrossRef
2.•
3.•
Invasive Cancer Incidence-United States. 2010. Morbidity and mortality weekly report. March 28, 2014. 63(12): 253-259. This article is important as it provides current statistics for invasive breast cancer incidence in the USA, published by the Center for Surveillance, Epidemiology and Laboratory Services, from the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services.
4.
Norrgard K. Protecting your genetic identity: GINA and HIPAA. Nat Educ. 2008;1(1):21.
5.
Robertson JA. The $1000 genome: ethical and legal issues in whole genome sequencing of individuals. InFocus. 2003;3(3):W35–42.
6.
Lea D. Genetic and genomic healthcare: ethical issues of importance to nurses. Online J Issues Nurs. 2008; 13(1): Manuscript 4.
7.
8.
Rothstein MA. Current in contemporary ethics: is GINA worth the wait? J Law, Med Ethics, Relig Cult East West Perspect Bioethics. Spring 2008: 174-178.
9.
10.
11.•
12.
13.
Vann JCJ. Slipping through the cracks of the breast and cervical cancer prevention and treatment act of 2000—a tragic case of failed access to care. J Nurs Law. 2011;13(3 & 4):96–106.CrossRef
14.•
Walcott FL, Dunn BK, DeShields J, Baquet C. The affordable care act and genetic testing for inheritable cancer syndromes: impact on high-risk underserved minorities. J Health Care Poor Underserved. February, 2014; 46-62. This article is important as it addresses the limitation in PPACA’ s provisions for men at risk of developing breast cancer as well as provisions for other cancer patients, other inheritable cancer syndromes associated with breast cancer and risk-reducing interventions for breast cancer not covered under PPACA.
15.
Feldman EA. The genetic information nondiscrimination act (GINA): public policy and medical practice in the age of personalized medicine. J Gen Intern Med. 2011;27(6):743–6.CrossRef
16.
Bard JS. When public health and genetic privacy collide: positive and normative theories explaining how ACA’s expansion of corporate wellness programs conflicts with GINA’s privacy rules. J Law Med Ethics. 2011;39(3):469–87.PubMed
17.
18.
Qureshi O, Warda Al, Rahaghi NF, Ferrer G, Ramirez J, Oliveira E, Rahaghi F. Physician’s views on targeted alpha-1 antitrypsin testing by respiratory therapists in PFT labs and their awareness of protections offered by the genetic information nondiscrimination act (GINA). Chest. 2013; 138 (4_MeetingAbstracts):456A. doi:10.​1378/​chest.​10400.
19.
Metadata
Title
The Genetic Information Nondiscrimination Act of 2008 (GINA) and the Patient Protection and Affordable Care Act of 2010 (PPACA): What They Mean for Breast Cancer Patients and Their Families
Author
Mary Beth Wilson Steck
Publication date
01-06-2015
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 2/2015
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-015-0182-3
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits